Diseases

GenPro's EpiMarkers are Agnostic to Disease or Disorder Type.

GenPro’s biomarker discovery technology is different from other approaches- it doesn’t require previous knowledge or understanding of the biological differences in two sets of subjects, and can be applied to diverse situations where commonly used methods have had little or no success.

The success of GenPro’s methods in these situations springs from our focus on the power of the immune system. Cells of the immune system, commonly known as White Blood Cells or WBCs, continually sense the state of health, stress, or disease in the body and record that information in their “epigenome”.

This is a universal process in the adaptive immune system, so information about virtually any disease state can be mined from the immune cells found in a standard blood draw. This information is incredibly complex, encoded in millions of DNA methylation sites, but also extremely useful after GenPro decodes it with proprietary algorithms.

GenPro has succeeded in identifying discriminating EpiMarkers in cancer, neurologic, and neuro-degenerative diseases and is continually pursuing new applications.

Cancer

  • Detection of invasive breast cancer and pre-invasive DCIS
  • Distinguishing DCIS with invasive vs non-invasive features
  • Predicting IO drug response in Non-Hodgkin’s Lymphoma
  • Predicting IO drug response in Non-Small Cell Lung Cancer (NSCLC)

Neurologic Diseases

  • Diagnosis of Cerebral Palsy
  • Detection of Parkinson’s Disease

Immune Mediated Diseases/Autoimmunity

This is an area of special interest and potential for GenPro technology since the immune cells are both drivers of the disease and sensors of the disease state. Both lead to distinct genome methylation patterns.

Potential indications include:

  • Rheumatoid Arthritis
  • Crohn’s Disease
  • Ulcerative Colititis
  • Multiple Sclerosis
  • Type I Diabetes
  • Lupus

Metabolic Diseases and Type II Diabetes

Published work from independent laboratories has demonstrated that patients with metabolic syndrome and Type II Diabetes have differential DNA methylation patterns in circulating white blood cells.